A new review indicates the gut microbiota may be a systemic driver of liver metastasis in small cell lung cancer (SCLC). This challenges the sole focus on tumor genetics, highlighting the gut-liver axis. Liver metastasis in SCLC is a critical challenge, marked by poor outcomes and limited treatment efficacy.
The review posits that microbial dysbiosis can foster a liver environment conducive to metastatic seeding, immune evasion, and treatment resistance. This occurs as dysbiosis compromises intestinal barrier integrity, allowing microbial products like lipopolysaccharide to enter the portal circulation, directly impacting the liver. These inflammatory signals can activate Kupffer cells and alter immune tolerance, transforming the liver into a pro-metastatic niche.
This process may also recruit immune-suppressing cells like myeloid-derived suppressor cells and regulatory T cells, weakening the body's defense against circulating SCLC cells.
Furthermore, microbial metabolites are implicated in liver remodeling that favors metastatic growth. Secondary bile acids, such as deoxycholic acid, are identified as key mediators that can activate hepatic stellate cells, increase extracellular matrix deposition, and promote fibrosis. This altered liver microenvironment can enhance tumor cell survival and colonization.
Conversely, beneficial short-chain fatty acids, like butyrate, may offer protection through anti-inflammatory and anti-fibrotic effects.
The review suggests that approaches targeting the microbiota could complement existing SCLC treatments. Potential strategies include probiotics, prebiotics, synbiotics, fecal microbiota transplantation, and advanced microbial therapeutics. The authors also emphasize avoiding unnecessary antibiotic use alongside immunotherapy and call for further research into microbial biomarkers and combination trials for patients with SCLC liver metastasis. While much of the evidence is translational, the gut microbiota is presented as a promising therapeutic target in this challenging disease.